Monthly Archives: April 2019

April 2019

A Strategic Collaboration in Epidermolysis Bullosa

Fibrocell Announces Collaboration with Castle Creek Pharmaceuticals to Develop and Commercialize FCX-007 Gene Therapy

- Fibrocell to receive up to $135 million, including up to $30 million in upfront, near-term and development payments and [...]

Making Progress for an Underserved Patient Community

© 2016 Castle Creek Pharma  -  Terms & Conditions  -  Privacy Policy

Powered by